ALERT

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

This study, building on the lessons learned from the ADAPT Study; will further investigate the effectiveness and safety of a combination pharmacotherapy (XR-NTX; as Vivitrol® plus once-daily bupropion extended-release tablets) for methamphetamine use disorder.

CTN Protocol ID:

CTN-0068

Status:

Completed

ClinicalTrials.gov ID:

NCT03078075

Principal Investigator(s)

Madhukar H. Trivedi, M.D.

Betty Jo Hay Distinguished Chair in Mental Health Professor, Node Principal Investigator

University of Texas Southwestern Medical Center

Department of Psychiatry

5323 Harry Hines Boulevard
Dallas, TX 75390
United States

madhukar.trivedi@utsouthwestern.edu